Neuvera has launched a two-step moisturizer bundle built on its patented Peptide G63 technology, citing a 2025 randomized trial in 60 women aged 60 to 90. That trial tested a different topical peptide formulation, not Neuvera's products.
Telangana's drug regulator TG SAFE has warned against buying or self-administering unapproved weight-loss drugs and experimental peptides sold on Telegram and other online platforms, naming BPC-157, GHK-Cu, retatrutide and tesamorelin. The advisory says such products may be contaminated, mislabelled or untested for sterility, and directs doctors not to prescribe them.
A FindArticles roundup collects six recurring points about GHK-Cu, the copper tripeptide widely studied in a skin context. Its sharpest argument is that raw research material and a tested consumer cosmetic are not the same thing.
A HuffPost feature on The Ordinary's $32 copper peptide serum pairs enthusiastic reviews from shoppers over 60 with a dermatologist who calls the delivery question unsettled. No published trial or outcome figure appears anywhere in the piece.
Eli Lilly and Novo Nordisk presented data associating their GLP-1 drugs with molecular ages two to three years younger than placebo. The findings have not been peer reviewed or analyzed by a third party, and the trials enrolled people who were already overweight and diabetic.
Gelita, Rousselot and Puredia told Personal Care Insights that GLP-1 use and preventative Gen Z routines are reshaping demand for collagen peptides. One supplier also said the collagen-stimulating peptides generating the most interest still lack substantial human trial data.
A study in Cell Death Discovery reports that the mitochondrial-derived peptide MOTS-c protected retinal vessel lining cells in high-glucose cultures and diabetic mice, acting through the enzyme PLA2G6. The work is preclinical, and the authors say delivery, dosing and safety questions remain unaddressed.
Retatrutide, a triple GLP-1, GIP and glucagon receptor agonist, is in phase 3 trials with trial weight loss that one principal investigator compared to bariatric surgery. A separate BMJ case report describes refractory nausea in a woman injected with an unverified product reported to contain it.
Novo Nordisk and Eli Lilly scientists told an anti-aging conference that semaglutide and tirzepatide slowed users' molecular aging clocks by two to four years against placebo. Neither analysis has been peer reviewed, and both were run in-house by the drugmakers.
Eli Lilly and Novo Nordisk presented exploratory aging-clock data on tirzepatide and semaglutide at a Harvard research meeting, with some models estimating biological age reductions of a few years. The analyses are preliminary, the clocks disagree with each other, and the only lifespan result so far is in mice.
Collagen peptides are one of the best-selling supplement ingredients in the world, with a forecast 7.2 percent annual growth rate through 2035. The current research pool behind that market includes a frozen-dough study, a product description, and no human trial at all.
AgelessRx has launched a prescription copper peptide cream in 0.5% and 3% strengths, compounded by licensed U.S. pharmacies and priced from $99 a month. The company reports 99.8% purity testing, but no clinical trial of the formulation is cited in the announcement.
Novo Nordisk and Eli Lilly both reported lower molecular aging clock readings in people taking their GLP-1 drugs, but Novo's analysis is a preprint and Lilly's was a conference presentation. Novo's own authors wrote the findings stop short of establishing biological rejuvenation.
A sponsored explainer on GHK-Cu lays out theorized roles in gene expression, extracellular matrix biology and oxidative balance, all in hedged language. Its own citation list runs to fibroblast cultures, a veterinary wound study and three reviews by the same author.
The Precision Peptide Company has ordered 20,000 units of a 2 mg Thymosin Alpha-1 transdermal patch, its first commercial run of the product. The clinical review it cites covers subcutaneous injection, not the patch, which the company says is still in testing.
IndexBox projects the global peptide-infused tinted moisturizer market will grow at 7.2% a year through 2035, reaching an index of 198 against a 2025 baseline of 100. The same report concedes that growth depends on moving beyond marketing hype to demonstrable results.
A market study projects 7.2% annual growth for glutathione through 2035 on beauty and longevity demand, while the FDA has posted a nationwide recall of compounded injectable glutathione over elevated endotoxin levels. Neither source cites a clinical trial for the claims the category is sold on.
A dermatologist interview published by E Online makes the case for copper peptides as an anti-aging ingredient, citing collagen signaling, antioxidant properties and better tolerability than retinol. No study, figure or sample size appears anywhere in the piece, which closes with a Prime Day serum roundup.
IndexBox projects the global peptide face serum market growing at a 6.2% compound annual rate through 2035, reaching roughly $3.8 billion. The same report names regulatory scrutiny of anti-aging claims as one of two main constraints on that growth.
A Frontiers in Nutrition review of 76 references reports that intermittent fasting produces weight and HbA1c changes comparable to continuous calorie restriction, with adherence differing sharply between protocols. The paper's four proposed timing-specific mechanisms rest largely on rodent studies the authors say human trials have yet to validate.
A new IndexBox category forecast projects the global glutathione market growing at a 7.2% compound annual rate through 2035, driven by beauty-from-within and longevity demand. The same report names unsettled structure and function claim rules as the key watchpoint for its premium tier.
Khloe Kardashian has praised Omi Women's Hair Growth Peptides on the record, calling the supplement the best thing that has happened to her hair. The formula's headline ingredient is a patented keratin-derived peptide complex, and every claim about it currently comes from the brand rather than a published trial.
Allure's 2026 peptide serum roundup names seven formulas, quotes dermatologists on mechanism, and leans on the phrase "Botox in a bottle" more than once. What it does not include is a named study, a participant count, or any denominator behind the eight-week timeline it quotes.
A newswire release says a September 2025 Biogerontology study reported dose-dependent telomere lengthening in human cell lines exposed to the tetrapeptide Epitalon. The work was done in cultured cells, and the release itself says it does not show any effect on human aging.
Karnataka's drug regulator sought details and Bengaluru's first "peptide party" was called off, but Mint's reporting found a grey market that never paused. Chainalysis put grey market peptide transactions above a $100 million run rate in 2026, up from around $1 million per quarter in 2024.
A narrative review in Clinics in Dermatology reports that studies of GLP-1 receptor agonists in hidradenitis suppurativa have described improvements in disease activity, quality of life and healthcare utilization. It also notes that no randomized controlled trial has ever tested the drug class in the disease.
A JACC: Case Reports paper describes an 82-year-old heart failure patient whose mean pulmonary artery pressure fell 10 mm Hg after semaglutide was added to device-guided management. It is a single case with no control group, and the authors call for larger studies.
An RTE report examines the social media boom in self-administered peptide injections and the near-total absence of human trials behind the claims. An endocrinologist calls the biochemistry sound but says it is far too early to use these substances in people.
Grazia's beauty desk has reviewed Byoma's new £21.99 Longevit-8 Peptide Serum, which blends peptides with niacinamide, ceramides and PDRN. The brand's cited trial results, 96% and 85%, arrive without a participant count or a published study.
A study in Food Science & Nutrition presents a validated method for measuring collagen peptide molecular weight inside real functional beverages, where additives like vitamin C and EGCG were shown to masquerade as tiny peptides. The fix is a 20.5-minute chromatographic cutoff and cubic rather than linear curve fitting.
A Frontiers in Nutrition review places declining NAD+ metabolism at the center of brain aging, linking vitamin B3 precursors, exercise and gut microbiota through shared signaling pathways. The authors note most supporting evidence is preclinical and say clinical relevance in neurodegenerative disease is not yet established.
NAD+ is sold as both a clinic infusion and an oral precursor, but none of the current coverage names a human trial, a dose or an outcome figure. A New York medical examiner has ruled one infusion death a homicide, while dermatologists are still publicly asking whether the category is hope or hype.
Elm Biosciences, co-founded by Martha Stewart and dermatologist Dr. Dhaval Bhanusali, launched a $45 peptide lip serum in four shades on September 22. The brand cites a dermatologist-supervised perception study of 54 women over seven days, with no published outcome figures.
Allergan Aesthetics presented two single-center studies of skincare regimens in people taking weight loss medications, reporting improvements in selected skin quality measures. The combined enrollment across both studies was 20 participants, and the company says larger research is needed.
A preclinical study reports that semaglutide started late in life was associated with a 12% longer median lifespan in female mice, plus better memory, endurance and glucose control. The catch is a control group that died earlier than this strain usually does, which leaves an alternative explanation open.
An FDA advisory committee voted in July to recommend BPC-157, KPV, TB-500, MOTS-c, Semax and epitalon for the 503A Bulks List, rejecting only emideltide. A Houston clinic is warning patients that the vote carries no immediate legal effect and that the rulemaking process has not started.
Jennifer Aniston told The Wall Street Journal in 2023 that weekly peptide injections were the future of skincare, but dermatologists quoted by Grazia say the injectable market still lacks human safety trials. The FDA has warned against these products, and the AMA says the evidence is not there to recommend them.
A review in World Journal of Transplantation looks at whether GLP-1 and GLP-1/GIP receptor agonists could help manage obesity in liver transplant recipients. The authors say long-term safety, dosing and outcomes remain insufficiently studied in this population.
Gelagen has launched a beauty gummy combining collagen peptides, hyaluronic acid, vitamin C, and grape seed extract, framing it as a dietary supplement rather than a topical product. The announcement includes ingredient rationale but no clinical trial, study, or outcome figure for the finished formula.
A Brand Desk article on WION frames Thymalin, a thymic peptide complex, as a model for studying peptide-mediated cellular regulation, gene expression and immune signaling. It cites no study, no researcher and no figure, and closes with a plug for a peptide supplier.
An NIH-funded study reported that semaglutide extended median lifespan by nearly 100 days in older mice and outperformed calorie restriction on memory and metabolic measures. The researchers say the findings do not show that GLP-1 drugs can extend human lifespan.
Byoma's Longevit-8 Peptide Serum pairs a GHK-Cu peptide blend with ceramides and Phyto-PDRN for $25.99, and shoppers are rating it five stars on Ulta.com. What the coverage does not include is a single published study, trial or outcome figure.
A paid advertorial on Newswire examines NEOLISE Renewal, a compounded four-peptide injectable protocol priced at $897 to $2,868 per term. It reports no FDA approval for GHK-Cu, BPC-157, TB-500 or KPV as used in the formulation, and unpublished identities for the prescribing group and pharmacy.
Dermatologists and longevity researchers are urging patients not to inject GHK-Cu, the copper peptide long sold in serums, because no published human study covers the injectable form. An FDA advisory panel is scheduled to review the evidence in February.
An Allure beauty editor tested a $350 compounded GHK-Cu cream for eight weeks, then asked a dermatologist, a pharmacist and a cosmetic chemist whether the prescription route was worth it. All three were skeptical, and the published human data on copper peptides remains small and largely brand-funded.
A Nature Medicine analysis pooled 51 intervention studies through a single panel of 16 epigenetic clocks and 94 other methylation markers. Diet, exercise, metformin, semaglutide and anti-TNF therapies moved the biomarkers; over-the-counter supplements did not produce consistent evidence.
Gaja Beauty Supplies LLC says its new face serum is the first to combine 2% GHK-Cu copper peptides with bee venom in a single stable formula. The announcement contains no trial, no participant count and no published data on the combination.
Karnataka's drug regulator served notice on a Bengaluru "peptide party" featuring peptide tastings, and the event was canceled. Doctors quoted in the report warn that approved peptide medicines and experimental compounds sold online are not the same category.
A Nature Communications study found that participants taking weekly semaglutide showed slowed epigenetic aging markers across blood, brain, heart, liver, and kidney cells over 32 weeks. The trial was small and limited to adults with HIV-associated lipohypertrophy, and the lead author says the work does not show aging being reversed.
A review in Hormone and Metabolic Research surveys GLP-1 and melanocortin-4 receptor agonists, including the dual and triple agents now dominating the obesity pipeline. It carries no new trial data, and the abstract states no outcome figures.
A Style Rave feature says copper peptide GHK-Cu has a decades-long research history in wound healing and tissue repair, but an evidence base thinner than that of retinoids. Laboratory and some human studies have reported changes in skin thickness, density and collagen-related activity, though larger standardized trials are still needed.
A paid advertorial promotes Copper Snap, a facial serum with a brand-stated 10% GHK-Cu concentration and SNAP-8, at $139 to $229 per order. No full ingredient list, no third-party lab verification, and no trial on the finished product appear in the materials reviewed.
Us Weekly's affiliate shopping feature recommends Londontown's Peptide Serum Concentrate for brittle nails, crediting a blend of cranberry peptides, aloe, glycerin and panthenol. No trial, figure or clinician appears anywhere in the piece, and the only support offered is a single customer review.
A Quebec court has granted Health Canada a permanent injunction against a company selling unauthorized injectable peptides, as researchers describe a consumer market moving faster than regulation. Popular online compounds including BPC-157 and KPV have little or no human evidence behind them.
GHK-Cu has decades of mechanistic and cell-culture research behind it, and dermatologists say its wound-healing history is the most clinically established part. Controlled human trials on the aging-skin uses it is now marketed for remain thin.
A Hartford HealthCare interview with Joe Li, DO, separates peptide medications with clinical evidence behind them from the injections sold online for recovery and anti-aging. The piece names BPC-157, ipamorelin and CJC-1295 as compounds whose marketed uses are not backed by human research.
Scientific American reports that growth hormone peptides sold through compounding pharmacies and longevity clinics have almost no trial evidence in healthy adults. Endocrinologists point to acromegaly risk and a gray-market analysis in which 40 to 70 percent of samples failed quality criteria.
Bengaluru's first invite-only "Peptide Party" was canceled after drawing more than 200 registrations for around 50 places, but The Indian Express reports the demand behind it is the real story. Researchers and the US FDA point to thin human evidence, contaminated samples and mislabeled vials in the online peptide market.
Neuvera has released a consumer guide arguing that topical collagen and peptides are not interchangeable, citing the 500 Dalton rule on skin penetration. The press release contains no trial, no outcome figure and no named researcher.
Two dermatologists told Yahoo Shopping that GHK-Cu, the blue-tinted copper peptide also listed as copper tripeptide-1, has an unusual research pedigree dating to a 1970s plasma study. They also say wound healing, not wrinkle erasure, is where the evidence is strongest.
The Australian Drug Foundation's new peptides explainer separates TGA-approved prescription medicines from the unapproved injectables sold online, and puts hard numbers on the gap. Testing of three retatrutide products found content ranging from half to nearly double the labeled dose.
A shopping roundup from E Online reports NAD+ has become the skincare industry's ingredient of the moment, with serums, creams and $55 eye patches now on shelves. What the feature does not name is a single published trial of NAD+ applied to skin.
A Vogue explainer quotes two board-certified dermatologists saying hydrolyzed collagen peptides may modestly improve skin hydration and elasticity, with results typically measured after 8 to 12 weeks. Both say supplements are an adjunct to sunscreen and retinoids, not a replacement.
Providers in the Charleston area told WCSC that marketing for peptides is running ahead of the clinical evidence, particularly for compounds sold outside FDA-approved channels. They said the approved GLP-1 drugs carry long-term safety data that many other peptides do not.
